Hirst DG - Search Results

1

The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.

Yakkundi A, McCallum L, O'Kane A, Dyer H, Worthington J, McKeen HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T. Yakkundi A, et al. Among authors: hirst dg. PLoS One. 2013;8(2):e55075. doi: 10.1371/journal.pone.0055075. Epub 2013 Feb 15. PLoS One. 2013. PMID: 23457460 Free PMC article.

2

FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.

McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, O'Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T. McKeen HD, et al. Among authors: hirst dg. Cancer Res. 2010 Feb 1;70(3):1090-100. doi: 10.1158/0008-5472.CAN-09-2515. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103631 Free article.

3

FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.

Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T. Valentine A, et al. Among authors: hirst dg. Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364036 Free PMC article.

4

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.

McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG. McCarthy HO, et al. Among authors: hirst dg. J Gene Med. 2007 Jun;9(6):511-20. doi: 10.1002/jgm.1045. J Gene Med. 2007. PMID: 17471586

5

A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling.

McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, O'Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson T. McKeen HD, et al. Among authors: hirst dg. Endocrinology. 2008 Nov;149(11):5724-34. doi: 10.1210/en.2008-0168. Epub 2008 Jul 31. Endocrinology. 2008. PMID: 18669603

6

Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.

Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T, Hirst DG. Adams C, et al. Among authors: hirst dg. J Gene Med. 2009 Feb;11(2):160-8. doi: 10.1002/jgm.1280. J Gene Med. 2009. PMID: 19062185

7

Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.

Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO. Coulter JA, et al. Among authors: hirst dg. J Gene Med. 2010 Sep;12(9):755-65. doi: 10.1002/jgm.1495. J Gene Med. 2010. PMID: 20821746

8

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG. Coulter JA, et al. Among authors: hirst dg. Gene Ther. 2008 Apr;15(7):495-503. doi: 10.1038/gt.2008.7. Epub 2008 Feb 7. Gene Ther. 2008. PMID: 18256696

9

Targeting nitric oxide for cancer therapy.

Hirst D, Robson T. Hirst D, et al. J Pharm Pharmacol. 2007 Jan;59(1):3-13. doi: 10.1211/jpp.59.1.0002. J Pharm Pharmacol. 2007. PMID: 17227615 Review.

10

Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy.

Hirst D, Robson T. Hirst D, et al. Curr Pharm Des. 2010;16(4):411-20. doi: 10.2174/138161210790232185. Curr Pharm Des. 2010. PMID: 20236069 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters